Concepedia

Christopher Jensen

CJ

Statistics

Publications

5

Citations

96

H-Index

5

Active since

2020

Affiliations

Albert Einstein College of Medicine(Current)

Biohaven Pharmaceuticals (United States)

Neurology Center of Southern California

Christopher Jensen is an author at Albert Einstein College of Medicine specializing in clinical pharmacology, headache management, and pharmacotherapy.

Publications per year

2020–2023

5

Publications

5

Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials

Richard B. Lipton, Andrew Blumenfeld, Christopher Jensen et al. · Cephalalgia · 2023 · 50 citations · Full text

, , +17

Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical trial (4976)

Robert Croop, Jennifer Madonia, Charles M. Conway et al. · Neurology · 2021 · 12 citations

, , +8

Long-Term Safety of Rimegepant 75 mg for the Acute Treatment of Migraine (Study 201) (4829)

Robert Croop, Gary Berman, David Kudrow et al. · Neurology · 2020 · 12 citations

, , +13

Oral Rimegepant 75 mg is Safe and Well Tolerated in Adults With Migraine and Cardiovascular Risk Factors: Results of a Multicenter, Long-Term, Open-Label Safety Study (1995)

Susan Hutchinson, Jack Schim, Richard B. Lipton et al. · Neurology · 2021 · 12 citations

, , +13

Expert consensus established around flexible, individualized migraine treatment utilizing a modified Delphi panel

Marlon Graf, Edward Kim, Iris Brewer et al. · Headache The Journal of Head and Face Pain · 2023 · 10 citations · Full text

, , +16

1–5 of 5